On October 8, 2024 Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, reported multiple presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 39th Annual Meeting, being held November 6-10, 2024, in Houston, TX (Press release, Sapience Therapeutics, OCT 8, 2024, View Source [SID1234647095]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are below:
ST101 Presentation Details (Oral Presentation and Poster):
Title: "ST101, an inhibitor of the transcription factor C/EBPß, promotes an immune-active tumor microenvironment in a window of opportunity (WoO) study of patients with glioblastoma (GBM)"
Abstract #: 991
Oral Presentation
Session Title: Biotech Breakthroughs – Solid Tumor IO at the Tipping Point
Date/Time: Friday, November 8, 2024, 1:45 pm – 3:20 pm CST
Session Location: George R. Brown Convention Center, Level 3 – Grand Ballroom B
Presenting Author: Jim Rotolo, Ph.D., SVP, Research & Translational Sciences, Sapience Therapeutics
Poster Presentation
Session: Poster Hall
Date/Time:
Friday, November 8, 2024: 9:00 am – 7:00 pm CST
Saturday, November 9, 2024: 9:00 am – 8:30 pm CST
Session Location: George R. Brown Convention Center, Level 1 – Exhibit Halls AB
ST316 Poster Presentation Details:
Title: "ST316, a peptide antagonist of ß-Catenin, depletes immunosuppressive myeloid cell populations and enhances anti-cancer immune responses in in vivo tumor models and in patients"
Abstract #: 1451
Session: Poster Hall
Date/Time:
Friday, November 8, 2024, 9:00 am – 7:00 pm CST
Saturday, November 9, 2024, 9:00 am – 8:30 pm CST
Session Location: George R. Brown Convention Center, Level 1 – Exhibit Halls AB
Presenting Author: Claudio Scuoppo, Ph.D., Principal Scientist, Sapience Therapeutics
More information can be found on the SITC (Free SITC Whitepaper) website.
About ST101
ST101, a first-in-class antagonist of C/EBPβ, has completed the main portion of a Phase 2 dose expansion study in recurrent GBM (rGBM) (NCT04478279). An ongoing window-of-opportunity sub-study is evaluating ST101 as a monotherapy in patients with rGBM and in combination with radiation and temozolomide in patients with newly diagnosed GBM (ndGBM), with patients receiving ST101 before and after surgical resection in both cohorts. ST101 has been granted Fast Track designation for rGBM from the U.S. FDA and orphan designations for glioma from the U.S. FDA and the European Commission.
About ST316
ST316 is a first-in-class peptide antagonist of the interaction between β-catenin and its co-activator, BCL9, a complex responsible for driving oncogene expression in multiple cancers where aberrant Wnt/β-catenin pathway signaling is observed. ST316 is being evaluated in the Phase 2 portion of a Phase 1-2 dose-escalation and expansion study (NCT05848739). The Phase 1 portion completed enrollment in July 2024. In the Phase 2 dose expansion, ST316 is being tested in colorectal cancer patients in combination with relevant standards of care and in multiple lines of treatment. Sapience is conducting the Phase 2 study across several sites in the United States.